Rodney Griffin
Family Medicine · Magnolia, ARNPI 1023018439
Payments from drug & device makers
Across 261 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$465
- Pfizer$352
- Johnson & Johnson$303
- Novo Nordisk$301
- Amgen$256
- Astellas Pharma US Inc$242
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,820100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $465 |
| Pfizer | 25 | $352 |
| Johnson & Johnson | 24 | $303 |
| Novo Nordisk | 21 | $301 |
| Amgen | 18 | $256 |
| Astellas Pharma US Inc | 16 | $242 |
| Abbott | 10 | $208 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $206 |
| Novartis | 13 | $173 |
| Boehringer Ingelheim | 11 | $169 |
| Lilly USA, LLC | 11 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $120 |
| E.r. Squibb & Sons, L.L.C. | 8 | $117 |
| Amarin Pharma, Inc. | 7 | $114 |
| Merck | 7 | $112 |
| GSK | 6 | $93 |
| Genentech USA, Inc. | 4 | $72 |
| Medtronic(2 entities) | 4 | $68 |
| AstraZeneca(2 entities) | 4 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| Exact Sciences | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Dexcom, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,820 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $14,520 |
| JardianceEmpagliflozin | 15 | $10,413 |
| Entacapone | 12 | $1,974 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,040 |
| SynthroidLevothyroxine Sodium | 12 | $955 |
| Omeprazole | 40 | $677 |
| Levothyroxine Sodium | 59 | $633 |
| Potassium Chloride | 32 | $514 |
| Atorvastatin Calcium | 52 | $449 |
| Simvastatin | 74 | $426 |
| Gabapentin | 44 | $422 |
| Pantoprazole Sodium | 33 | $399 |
| Metoprolol Succinate | 29 | $356 |
| Tamsulosin Hcl | 14 | $298 |
| Amlodipine Besylate | 71 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $352 | $14,52018 claims |
| Boehringer IngelheimJardiance | $169 | $10,41315 claims |
| AbbVieSynthroid | $465 | $95512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Magnolia
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.